KR20070061493A - Health functional food composition comprising red ginseng acid polysaccharide and lycium chinense extract for hyperlipidemia improvement function - Google Patents

Health functional food composition comprising red ginseng acid polysaccharide and lycium chinense extract for hyperlipidemia improvement function Download PDF

Info

Publication number
KR20070061493A
KR20070061493A KR1020070041348A KR20070041348A KR20070061493A KR 20070061493 A KR20070061493 A KR 20070061493A KR 1020070041348 A KR1020070041348 A KR 1020070041348A KR 20070041348 A KR20070041348 A KR 20070041348A KR 20070061493 A KR20070061493 A KR 20070061493A
Authority
KR
South Korea
Prior art keywords
weight
rgap
cholesterol
red ginseng
hyperlipidemia
Prior art date
Application number
KR1020070041348A
Other languages
Korean (ko)
Other versions
KR100815277B1 (en
Inventor
박종대
곽이성
위재준
송용범
경종수
Original Assignee
주식회사 케이티앤지
주식회사 한국인삼공사
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by 주식회사 케이티앤지, 주식회사 한국인삼공사 filed Critical 주식회사 케이티앤지
Priority to KR1020070041348A priority Critical patent/KR100815277B1/en
Publication of KR20070061493A publication Critical patent/KR20070061493A/en
Application granted granted Critical
Publication of KR100815277B1 publication Critical patent/KR100815277B1/en

Links

Classifications

    • AHUMAN NECESSITIES
    • A23FOODS OR FOODSTUFFS; TREATMENT THEREOF, NOT COVERED BY OTHER CLASSES
    • A23LFOODS, FOODSTUFFS, OR NON-ALCOHOLIC BEVERAGES, NOT COVERED BY SUBCLASSES A21D OR A23B-A23J; THEIR PREPARATION OR TREATMENT, e.g. COOKING, MODIFICATION OF NUTRITIVE QUALITIES, PHYSICAL TREATMENT; PRESERVATION OF FOODS OR FOODSTUFFS, IN GENERAL
    • A23L33/00Modifying nutritive qualities of foods; Dietetic products; Preparation or treatment thereof
    • A23L33/10Modifying nutritive qualities of foods; Dietetic products; Preparation or treatment thereof using additives
    • A23L33/105Plant extracts, their artificial duplicates or their derivatives
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K36/00Medicinal preparations of undetermined constitution containing material from algae, lichens, fungi or plants, or derivatives thereof, e.g. traditional herbal medicines
    • A61K36/18Magnoliophyta (angiosperms)
    • A61K36/185Magnoliopsida (dicotyledons)
    • A61K36/25Araliaceae (Ginseng family), e.g. ivy, aralia, schefflera or tetrapanax
    • A61K36/258Panax (ginseng)
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K36/00Medicinal preparations of undetermined constitution containing material from algae, lichens, fungi or plants, or derivatives thereof, e.g. traditional herbal medicines
    • A61K36/18Magnoliophyta (angiosperms)
    • A61K36/185Magnoliopsida (dicotyledons)
    • A61K36/81Solanaceae (Potato family), e.g. tobacco, nightshade, tomato, belladonna, capsicum or jimsonweed
    • A61K36/815Lycium (desert-thorn)
    • AHUMAN NECESSITIES
    • A23FOODS OR FOODSTUFFS; TREATMENT THEREOF, NOT COVERED BY OTHER CLASSES
    • A23VINDEXING SCHEME RELATING TO FOODS, FOODSTUFFS OR NON-ALCOHOLIC BEVERAGES AND LACTIC OR PROPIONIC ACID BACTERIA USED IN FOODSTUFFS OR FOOD PREPARATION
    • A23V2002/00Food compositions, function of food ingredients or processes for food or foodstuffs
    • AHUMAN NECESSITIES
    • A23FOODS OR FOODSTUFFS; TREATMENT THEREOF, NOT COVERED BY OTHER CLASSES
    • A23VINDEXING SCHEME RELATING TO FOODS, FOODSTUFFS OR NON-ALCOHOLIC BEVERAGES AND LACTIC OR PROPIONIC ACID BACTERIA USED IN FOODSTUFFS OR FOOD PREPARATION
    • A23V2200/00Function of food ingredients
    • A23V2200/30Foods, ingredients or supplements having a functional effect on health
    • A23V2200/3262Foods, ingredients or supplements having a functional effect on health having an effect on blood cholesterol

Landscapes

  • Health & Medical Sciences (AREA)
  • Natural Medicines & Medicinal Plants (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Botany (AREA)
  • Mycology (AREA)
  • Chemical & Material Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Alternative & Traditional Medicine (AREA)
  • Microbiology (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • Biotechnology (AREA)
  • Medical Informatics (AREA)
  • Medicinal Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Epidemiology (AREA)
  • Animal Behavior & Ethology (AREA)
  • Polymers & Plastics (AREA)
  • Nutrition Science (AREA)
  • Food Science & Technology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicines Containing Plant Substances (AREA)

Abstract

A health functional food composition containing red ginseng acid polysaccharide(RGAP) and Lycium fruit extract as an active ingredient is provided, which exhibits a hypercholesterolemia improving function on all of cholesterol and neutral fat and has synergistic effect on hypercholesterolemia improvement. The health functional food composition contains: red ginseng acid polysaccharide containing 41.6 to 60.0% by mole of glucuronic acid, 2.5 to 7.5% by mole of galacturonic acid, 18.8 to 33.4% by mole of glucose and 1.1 to 2.1% by mole of arabinose and having a molecular weight of 12,000 to 450,000 and Lycium fruit extract. For an example, 1kg red ginseng is extracted with 10L ethanol several times to produce RGAP; 1kg Lycium fruit is extracted with 8L water 3 times to produce Lycium fruit extract. Then, 5.0% by weight of the herbal composition containing 100mg RGAP and 100mg Lycium fruit extract is mixed with 65.0% by weight of starch, 17.5% by weight of lactose, 5.0% by weight of magnesium stearate, 2.5% by weight of vitamin C and 5.0% by weight of mannitol and tableted.

Description

홍삼 산성다당체 및 구기자추출물을 함유하며, 고지혈증 개선 기능을 갖는 건강기능식품 조성물{Health functional food composition comprising Red ginseng acid polysaccharide and Lycium chinense extract for hyperlipidemia improvement function}Health functional food composition comprising red ginseng acid polysaccharide and Lycium chinense extract for hyperlipidemia improvement function containing red ginseng acid polysaccharide and goji berry extract

본 발명은 대한민국 특허출원 제2005-32129호 및 대한민국 특허출원 제2005-32130호의 연속된 발명에 관한 것으로서, 고지혈증 개선 효과를 갖는 홍삼 산성다당체(Red ginseng acid polysaccharide: 이하 'RGAP'라 한다)의 보다 증진된 효과를 갖는 조성물에 관한 것이다.The present invention relates to the continuous invention of the Republic of Korea Patent Application No. 2005-32129 and the Republic of Korea Patent Application No. 2005-32130, more than the red ginseng acid polysaccharide (hereinafter referred to as 'RGAP') having a hyperlipidemic effect It relates to a composition having enhanced effects.

본 발명은 홍삼 산성다당체(RGAP) 및 구기자(Lycium chinense)추출물을 함유하며, 보다 강화된 고지혈증 개선 기능, 특히 콜레스테롤 및 중성지방 모두에 대하여 고지혈증 개선 기능을 나타낸다.The present invention red ginseng acid polysaccharide (RGAP) and gojija ( Lycium chinense ) extract and exhibits enhanced hyperlipidemic improvement, in particular hyperlipidemia improvement for both cholesterol and triglycerides.

고지혈증이란 혈액 속의 지방 성분이 높은 상태를 말한다. 즉 혈장 콜레스테롤이나 중성지방의 증가를 의미한다. 고지혈증은 그 자체로 어떤 증상을 나타내는 것이 아니라 혈중 콜레스테롤이나 중성지방의 증가로 인해 동맥경화, 고혈압, 심혈관계 질환 등의 위험요인이 되기 때문에 문제가 된다. 최근에는 서구화된 식습관의 변화로 인해 우리나라도 비만인 사람이 증가하고 있으며, 이들에게서 고지혈증이 수반된다. 고지혈증은 죽상동맥경화증을 일으켜 생명을 위협할 수 있고, 췌장염을 일으킬 수 있기 때문에 관리가 매우 중요하다. 특히 식이요법은 모든 고지혈증 증상 개선의 가장 기본이므로 1일 지방 섭취가 30%미만이 되어야 하고, 동물성 지방 대신 식물성 지방을 섭취해야 하며, 버터, 치즈, 우유, 소고기, 돼지고기, 닭고기, 초코렛, 마가린 등 포화지방이 많은 식품은 적게 복용해야 하는 등 제한되거나 주의해야 하는 음식이 많아 식생활에 장애가 많다. 따라서 고지혈증 환자 또는 이를 예방하고자 하는 일반인들의 식생활을 개선하기 위한 기능성 식품소재를 개발할 필요가 있다.Hyperlipidemia refers to a condition in which fat is high in the blood. This means an increase in plasma cholesterol or triglycerides. Hyperlipidemia is not a symptom by itself, but a problem because it is a risk factor such as atherosclerosis, hypertension, and cardiovascular disease due to the increase of blood cholesterol or triglyceride. Recently, due to the changes in westernized eating habits in Korea, an increasing number of people are obese, hyperlipidemia is accompanied by them. Hyperlipidemia is very important because it can cause atherosclerosis to be life-threatening and cause pancreatitis. In particular, diet is the most basic of all hyperlipidemia symptoms, so daily fat intake should be less than 30%, vegetable fat instead of animal fat, butter, cheese, milk, beef, pork, chicken, chocolate, margarine Many foods that are high in saturated fat, such as low intake should be limited or careful food, many eating disorders. Therefore, it is necessary to develop a functional food material to improve the diet of hyperlipidemic patients or the general public who wants to prevent it.

콜레스테롤은 세포 원형질막의 구성성분, 부신과 생식선에서의 스테로이드 호르몬의 원료, 담즙의 원료, 혈중 지단백의 구성성분으로 필수적이다. 콜레스테롤은 약80%가 간에서 자체적으로 합성되며 나머지 20%가 음식으로부터 얻어진다. 간에서 생합성되는 콜레스테롤을 지나치게 많을 경우를 내인성 고지혈증이라고 하고, 음식을 과잉으로 섭취하여 콜레스테롤 함량이 높을 경우를 외인성 고지혈증이라고 부른다. 내인성 고지혈증은 콜레스테롤의 대사 이상일 경우가 많으며, 외인성 고지혈증은 음식을 과잉섭취하게 되는 경우 발생한다. 콜레스테롤 조절이란 체내 콜레스테롤 수준을 적절한 범위로 조절하여 혈장과 조직, 특히 혈관에 콜레스테롤 축적 이 일어나지 않게 함을 말한다. 체내 콜레스테롤이 축적될 경우 고콜레스테롤혈증이 나타나며, 장기간에 걸쳐 콜레스테롤이 조절되지 않을 경우 동맥경화증으로 이어진다.Cholesterol is essential as a component of cellular plasma membranes, as a source of steroid hormones in the adrenal and gonads, as a source of bile, and as a component of blood lipoproteins. About 80% of cholesterol is synthesized by the liver itself and the remaining 20% is obtained from food. Too much cholesterol biosynthesized in the liver is called endogenous hyperlipidemia, and excessive food intake of high cholesterol content is called exogenous hyperlipidemia. Endogenous hyperlipidemia is often an abnormality in cholesterol metabolism, and exogenous hyperlipidemia occurs when food is ingested excessively. Cholesterol control is the regulation of cholesterol levels within the body to prevent the accumulation of cholesterol in plasma and tissues, especially blood vessels. Hypercholesterolemia occurs when the body's cholesterol accumulates, leading to atherosclerosis if cholesterol is not controlled over a long period of time.

중성지방은 음식으로 섭취된 지방이 장에서 흡수되어 혈액으로 들어가거나 간에서 과잉 열량이 지방으로 전환된 후 혈액으로 들어감으로서 생성되므로 기름진 음식을 많이 섭취하면 외인성 고지혈증이 유발될 확률이 높다. 또한 혈중 중성지방의 농도가 높아도 심혈관계질환의 발생빈도가 높아진다. 특히 한국인의 경우 에너지 섭취량 중 탄수화물이 차지하는 비율이 높은 관계로 혈청 중성지방의 농도가 고지혈증의 판정에 중요하다.Triglycerides are produced by the absorption of fat from food into the intestine and into the blood or by the excess calories from the liver into the blood, which leads to exogenous hyperlipidemia. High levels of triglycerides in the blood also increase the incidence of cardiovascular disease. In particular, Koreans have a high percentage of carbohydrates in their energy intake, so serum triglyceride levels are important for the determination of hyperlipidemia.

따라서 고지혈증을 위한 여러 천연 식품 소재들 중에서도 인체에 반드시 필요한 콜레스테롤은 유지하면서, 고지혈증을 유발할 수 있는 콜레스테롤 또는 중성지방의 농도를 감소시키는 기능을 갖는 물질의 개발이 필요하다.Therefore, among the various natural food ingredients for hyperlipidemia, it is necessary to develop a substance having a function of reducing the concentration of cholesterol or triglycerides that can cause hyperlipidemia while maintaining the cholesterol necessary for the human body.

한편, 예로부터 불로·장생·익기(益氣)·경신(輕身)의 명약으로 일컬어지고 있는 인삼은 말초혈관을 확장하여 혈류순환을 개선시키는 등 동맥경화증의 발생억제와 혈관내피세포의 손상을 방어해주는 효과가 있음이 알려져 있다(N.D. Kim. Vasorelaxant effect of ginseng and role of endothelium. J. Ginseng Res . 16(1). 78. 1992). 상세하게 고려인삼을 성인남녀에게 투여한 임상실험결과에서 고밀도 지단백 콜레스테롤 (HDL-cholesterol)의 증가, 동맥경화지수(atherogenic index)의 개선 및 베타-지단백(β-lipoprotein)의 저하 등 동맥경화의 예방에 유효 한 것으로 밝혀진 바 있다(中西辛三. 1980. 臨床と 硏究, 57(9), 323, M. Yamamoto, T. Uemura, S. Nkama, M. Uemiya and A. Kumagai. 1983. Serum HDL-cholesterol increasing and fatty liver-improving actions of Panax ginseng in high cholesterol diet-fed rats with clinical effect on hyperlipidemia in man. A. J. of Chinese Medicine . 4. 96-101).On the other hand, ginseng, which is known as a medicine for brazier, maturity, ripening, and nerves, has been shown to prevent the development of arteriosclerosis and damage vascular endothelial cells by expanding peripheral blood vessels and improving blood circulation. (ND Kim. Vasorelaxant effect of ginseng and role of endothelium. J. Ginseng Res . 16 (1). 78. 1992). In detail, the results of clinical trials in which Korean ginseng was administered to adult men and women prevented arteriosclerosis, such as the increase of HDL-cholesterol, the improvement of the atherosclerotic index and the decrease of β-lipoprotein. It was found to be effective in (Moshiyama, 1980. 臨 床 と 硏 究, 57 (9), 323, M. Yamamoto, T. Uemura, S. Nkama, M. Uemiya and A. Kumagai. 1983. Serum HDL -cholesterol increasing and fatty liver-improving actions of Panax ginseng in high cholesterol diet-fed rats with clinical effect on hyperlipidemia in man. AJ of Chinese Medicine . 4. 96-101).

특히, 인삼의 성분 중 사포닌 성분은 혈중 콜레스테롤의 지질대사와 관련된 효소활성을 촉진하고(C.N. Joo. 1980. The effect of ginseng saponin on hypercholesterolemia induced by prolonged cholesterol feeding in rabbits. Korean Biochemical . J. 13(1), 51-59), 콜레스테롤의 전환(cholesterol turnover)을 촉진함으로써 동맥경화의 중요한 위험인자인 고지혈증을 개선하는 효과가 있다고 알려져 있으며(M. Yamamoto and T. Uemura. 1984. Long-term ginseng effects on hyperlipidaemia in man with further study of its action on atherogenesis and fatty liver in rats. Proc . 4 th Int'l Ginseng Symp . 13-20), 인삼사포닌 성분 중 진세노사이드 알비투 (ginsenoside Rb2)가 혈중 콜레스테롤 수치저하와 배설촉진, 고콜레스테롤혈증으로 야기되는 동맥경화의 개선효과를 나타낸다(T. Yokozawa et. al. 1985. Studies on the mechanism of the hypoglycemic activity of ginsenoside-Rb2 in streptozotocin-diabetic rats. Chem . Pharm . Bull . 33. 869-872)고 알려져 있다.In particular, the saponin component of the components of ginseng promotes the enzyme activity associated with the lipid metabolism of cholesterol, and (CN Joo. 1980. The effect of ginseng saponin on hypercholesterolemia induced by prolonged cholesterol feeding in rabbits. Korean Biochemical. J. 13 (1 ), 51-59), have been shown to promote hypercholesterolemia, an important risk factor for atherosclerosis by promoting cholesterol turnover (M. Yamamoto and T. Uemura. 1984. Long-term ginseng effects on hyperlipidaemia in man with further study of its action on atherogenesis and fatty liver in rats. Proc. 4 th Int'l Ginseng Symp . 13-20), Ginsenoside albitus (ginsenoside Rb 2 ) among ginseng saponins has been shown to improve the arteriosclerosis caused by lowering cholesterol levels, promoting excretion and hypercholesterolemia (T. Yokozawa et. Al. 1985). .. Studies on the mechanism of the hypoglycemic activity of ginsenoside Rb-2 in streptozotocin-diabetic rats. Chem. Pharm. Bull 33. 869-872) and is known.

인산의 성분 중 비사포닌 성분인 다당류는 면역 조절효과, 항암 효과, 항당뇨 효과 및 항위궤양 작용 등이 보고되어 있으며, 중국에서는 암치료에 임상적으로 다당 분획을 사용하고 위암, 대장암에 대해서도 일정한 효과를 나타낸다고 보고하고 있다. 이러한 비사포닌 수용성 물질은 백삼으로부터 글리칸 (glycan)인 파낙산 A - U (panaxan A - U) 등 21종이 분리 보고 되었다. 그 중 산성다당체는 8종이고 나머지는 중성다당체로 알려져 있다. 일반적으로, 산성다당체는 다당류에 갈락투론산 (galacturonic acid), 글루쿠론산 (glucuronic acid) 및 만뉴론산 (mannuronic acid)이 결합된 다당체로서 분자량이 보통 15,000 이상이다. 특히, 산성다당체의 경우 암세포 분비 독소 (Toxohormone L) 길항 작용, 체지방 분해 억제 및 암환자 체중감소 억제효과가 알려져 있다. 또한, 백삼의 산성다당체 분획이 항암제 (cyclophosphamide) 면역독성 억제효과와 암세포(sarcoma-180) 이식 마우스의 암 발생 억제 및 망내계의 탐식활성 증대효과를 가지고 있음이 본 발명자들에 의해 보고된 바 있다(Kim, Y. S. et al. 1990. Arch. Pharm. Res., 13:330). 아울러, 대한민국 등록특허 제144130호에는 백삼으로부터 분리된 단백다당체인 진산은 글루코오스 및 갈락토오스가 40 내지 50%, 산성당인 갈락투론산이 41 내지 45% 함유되어 있으며 단백질이 3.7 내지 5.2% 함유되어 있고 분자량이 50 내지 150 kD으로서 면역증강 효과를 나타낸다고 알려져 있다. 또한, 진산은 벤조피렌(Bezopyrene, BP)으로 유도한 마우스 폐종양에 대한 면역조절 기능으로서 항암효과를 보여주고 내생 싸이토카인 유도체(cytokine inducer)로서 작용하여 암의 면역학적 예방효과를 보여준다고 보고되고 있다.Among the components of phosphoric acid, polysaccharides, which are non-saponins, have been reported to have immunomodulatory effect, anticancer effect, antidiabetic effect, and anti-gastric ulcer effect.In China, polysaccharide fractions are used clinically to treat cancer and constant for stomach and colorectal cancer. It is reported to be effective. 21 non-saponin water-soluble substances have been reported from white ginseng, including glycan (panaxan A-U), a glycan. Among them, 8 kinds of acidic polysaccharides are known as neutral polysaccharides. Generally, acidic polysaccharides are polysaccharides in which galacturonic acid, glucuronic acid, and mannuronic acid are combined with polysaccharides, and have a molecular weight of 15,000 or more. In particular, in the case of acidic polysaccharides, cancer cell secretion toxin (Toxohormone L) antagonism, body fat degradation inhibition and cancer patients weight loss inhibitory effect is known. In addition, it has been reported by the present inventors that the acidic polysaccharide fraction of white ginseng has anti-cancer drug (cyclophosphamide) immunotoxicity inhibitory effect, cancer cell (sarcoma-180) transplantation mouse inhibition of cancer development and the phagocytic activity of the net system is enhanced. (Kim, YS et al. 1990. Arch. Pharm. Res., 13: 330). In addition, the Republic of Korea Patent No. 144130 is a protein polysaccharide isolated from white ginseng contains 40 to 50% glucose and galactose, 41 to 45% acidic sugar galacturonic acid, 3.7 to 5.2% protein and molecular weight It is said to exhibit an immunostimulating effect as 50-150 kD. In addition, zinic acid has been reported to show anticancer effects as an immunomodulatory function against mouse lung tumors induced by benzopyrene (BP) and to act as an endogenous cytokine derivative (cytokine inducer), showing an immunologically preventive effect of cancer.

건강기능식품의 소재로도 이용되고 있는 생약은 기원, 산지, 수치법 등에 따라 형태가 다르고 함유 성분과 약리 활성도 차이가 있다. 한방 처방에 사용되고 있는 생약 중에는 오랜 경험으로부터 단순히 신선한 재료를 그대로 혹은 건조된 것을 사용하는 것 이외에도 특정한 가공처리를 한 후 사용하는 예가 많다. 인삼도 가공조제인 수치에 따라 백삼 및 홍삼으로 분류된다. 백삼은 수삼을 그대로 건조 가공하는 것으로, 홍삼은 수삼(약 70% 수분 함유)을 증숙하여 건조 가공한 것이다. 홍삼은 수삼을 증숙·건조하므로 전분질이 호화되고 갈색화 반응이 촉진되어 외관은 담갈색 내지 적갈색을 띈다. 홍삼 제조시에 유효 성분에도 화학적 변화가 수반되는데, 인삼의 약효 성분으로 알려진 사포닌은 홍삼 제조시 일부가 수치에 의해 홍삼 특유의 사포닌으로 변환된다. 또한, 다당류도 이런 화학적 변화가 일어나며, 이는 본 발명자는 인삼의 단백 다당체와는 조성이 다른 홍삼 산성다당체(RGAP)가 생성됨을 밝혀내어 대한민국 특허 제450061호로 특허등록 한 바 있으며, 이런 RGAP는 항암 면역 조절제로서 유용하게 사용될 수 있음도 알려져 있다.Herbal medicines, which are also used as ingredients for health functional foods, vary in form depending on their origin, place of origin, and numerical methods, and have different constituents and pharmacological activities. Among the herbal medicines used for herbal medicines, there are many examples of using herbal medicines after specific processing, in addition to using fresh ingredients or dried ones. Ginseng is also classified into white and red ginseng according to the value of processing aid. White ginseng is processed by drying ginseng as it is, red ginseng is steamed by drying ginseng (containing about 70% water). As red ginseng steams and dries ginseng, starch is gelatinized and the browning reaction is accelerated, and the appearance is pale brown to reddish brown. The active ingredient in the preparation of red ginseng is accompanied by chemical changes, and saponins, known as ginseng's active ingredients, are partially converted into saponins unique to red ginseng by numerical values during red ginseng production. In addition, such chemical changes also occur in polysaccharides, and the present inventors have discovered that red ginseng acid polysaccharide (RGAP) having a composition different from that of ginseng protein polysaccharide has been registered and patented in Korean Patent No. 450061, and such RGAP is anti-cancer immunity. It is also known that it can be usefully used as a regulator.

한편, 구기자 (Lycium chinense)는 혈당강하작용, 간세포 보호작용이 있다고 알려져 있다(과학·백과사전출판사 편저. 1999. 약초의 성분과 이용. 일월서각. 서울. p.631). 윤 등 (Yoon CG, Jeon TW, Oh MJ, Lee GH, Jeong JH. 2000. Effect of the ethanol extract of Lycium chinense on the oxygen free radical and alcohol metabolizing enzyme activities in rats. J. Korean Soc. Food Sci. Nutr. 29: 268-273)은 구기자 추출물이 알콜 섭취로 인한 유해산소의 생성을 억제하고 알콜 대사 효소의 활성을 증가시켜 간손상의 가능성을 낮출 수 있다고 보고하였으며, 한 등(Han SH, Shin MK, Lee HS. 2001. Effect of Korean Gu-Gi-Ja tea on plasma hormone in Cd-administered rats. J. Korean Soc. Food. Sci. Nutr. 30: 1272-1277)은 구기자차를 카드뮴과 병합하여 투여한 실험군의 경우에 신장조직의 카드뮴함량은 카드뮴만 투여한 경우보다 유의적으로 낮은 것으로 보고하였다. 또한 박 등(Park YJ, Kim M, Bae SJ. 2002. Enhancement of anti-carcinogenic effect by combination of Lycii fructus with Vitamin C. J. Korean Soc. Food Sci. Nutr. 31: 143-148)은 구기자를 추출, 분획하여 4 종의 암세포주에 대한 증식억제 효과를 발표하였으며, 이외에도 김 등(Kim NJ, Youn WH, Hong ND. 1994. Pharmacological effects of Lycium chinensis. Kor. J. of Pharmacgnosy. 25: 264-271)은 혈당강하효과, 콜레스테롤농도 저하작용, 간기능 보호작용 등을 발표한 바 있다.Meanwhile, wolfberry ( Lycium Chinense is known to have hypoglycemic and hepatocellular protective effects (ed by Science and Encyclopedia Publishers, 1999. Ingredients and Uses of Herbs, Ilwol Seogwa, Seoul, p.631). Yoon CG, Jeon TW, Oh MJ, Lee GH, Jeong JH. 2000. Effect of the ethanol extract of Lycium chinense on the oxygen free radical and alcohol metabolizing enzyme activities in rats.J. Korean Soc.Food Sci.Nutr 29: 268-273) reported that goji berry extract may lower the possibility of liver damage by inhibiting the production of harmful oxygen by alcohol consumption and increasing the activity of alcohol metabolizing enzymes, Han SH, Shin MK, Lee HS.2001.Effect of Korean Gu-Gi-Ja tea on plasma hormone in Cd-administered rats.J. Korean Soc.Food.Sci.Nutr. 30: 1272-1277) In the experimental group, the cadmium content of the kidney tissue was reported to be significantly lower than that of the cadmium alone. Park YJ, Kim M, Bae SJ. 2002.Enhancement of anti-carcinogenic effect by combination of Lycii fructus with Vitamin CJ Korean Soc.Food Sci.Nutr. 31: 143-148) In addition, Kim NJ, Youn WH, Hong ND. 1994. Pharmacological effects of Lycium chinensis.Kor. J. of Pharmacgnosy. 25: 264-271 It has been reported to have a lowering effect, lowering cholesterol levels, and protecting liver function.

본 발명자들은 인삼 및 인삼의 성분인 사포닌 또는 다당류와는 조성이 전혀 다른 RGAP가 고지혈증 특히 중성지방의 농도를 특이적으로 감소시킴을 확인하고, 대한민국 특허출원 제2005-32130호를 출원한 바 있으나, RGAP는 중성지방에 대해서는 선택적인 억제효과를 갖는 반면, 콜레스테롤에 대해서는 그 효과가 상대적으로 적은 것에 따른 개선방안을 마련하고자 노력하였다.The present inventors confirmed that RGAP, which is completely different from ginseng and saponin or polysaccharide, which is a component of ginseng, specifically reduces the concentration of hyperlipidemia, especially triglycerides, and has filed Korean Patent Application No. 2005-32130. While RGAP has a selective inhibitory effect on triglycerides, RGAP has tried to come up with measures to improve the relatively small effect on cholesterol.

본 발명자들은 구기자추출물이 콜레스테롤 저하작용은 있는 점에 주목하였다. 그런데 구기자는 단독 투여시에는 그 효과가 매우 작아 콜레스테롤저하를 목적으로 그대로 사용하기에는 문제점이 있다.The inventors noted that goji berry extract has a cholesterol lowering effect. However, goji berries have a problem when used alone for the purpose of cholesterol reduction is very small when administered alone.

놀랍게도, 본 발명자들은 상기 RGAP와 구기자추출물을 병용 투여한 혼합조성물에서 콜레스테롤과 중성지방을 모두 억제하고 단독투여일 경우보다 더 높은 항고지혈증 시너지효과를 나타냄을 확인하고 본 발명을 완성하게 되었다.Surprisingly, the inventors of the present invention have confirmed that the mixed composition of RGAP and goji berry extract suppresses both cholesterol and triglycerides and shows a higher anti-hyperlipidemic synergistic effect than when administered alone.

본 발명은 고지혈증 개선 효과를 갖는 홍삼 산성다당체(RGAP)의 보다 증진된 고지혈증 개선 기능 특히, 콜레스테롤과 중성지방 수치를 모두 낮출 수 있는 건강기능식품 조성물을 제공하는 것을 목적으로 한다.It is an object of the present invention to provide a health functional food composition capable of lowering both cholesterol and triglyceride levels, particularly enhanced hyperlipidemic function of red ginseng acid polysaccharide (RGAP) having a hyperlipidemic effect.

상기와 같은 목적을 달성하기 위하여, 본 발명은 고지혈증 개선을 위한 홍삼 산성다당체(RGAP)와 구기자(Lycium chinense)추출물을 함유하는 건강기능식품 조성물을 제공한다.In order to achieve the above object, the present invention is red ginseng acid polysaccharide (RGAP) and gojija ( Lycium ) for improving hyperlipidemia chinense ) provides a nutraceutical composition containing the extract.

고지혈증은 중성지방(Triglyceride: TG)과 콜레스테롤(Cholesterol) 등의 지방대사가 제대로 이루어지지 않아 혈액 중에 지방량이 많아진 상태를 의미한다. 고 지혈증의 원인은 크게 음식 등의 외부적인 요인과, 유전, 지질대사의 이상 등 내부적인 요인으로 나뉜다. 콜레스테롤은 약80%가 간에서 자체적으로 합성되며 나머지 20%가 음식으로부터 얻어진다. 내인성 고지혈증은 콜레스테롤의 대사 이상일 경우가 많으며, 외인성 고지혈증은 음식으로부터 고콜레스테롤 음식을 과잉섭취하게 되었을 때 유발된다. 중성지방은 음식으로 섭취된 지방이 장에서 흡수되어 혈액으로 들어가거나 간에서 과잉 열량이 지방으로 전환된 후 혈액으로 들어감으로서 생성되므로 기름진 음식을 많이 섭취하면 내인성 고지혈증이 유발될 확률이 높다.Hyperlipidemia refers to a condition in which the amount of fat in the blood is increased because triglyceride (TG) and cholesterol (Cholesterol) are not properly metabolized. The causes of hyperlipidemia are largely divided into external factors such as food, and internal factors such as genetic and lipid metabolism abnormalities. About 80% of cholesterol is synthesized by the liver itself and the remaining 20% is obtained from food. Endogenous hyperlipidemia is often an abnormality in cholesterol metabolism, and exogenous hyperlipidemia is caused by excessive intake of high cholesterol food from food. Triglycerides are produced by the absorption of fat from food into the blood in the intestine and into the blood after excess calories from the liver are converted into fat, so eating a lot of fatty foods is likely to cause endogenous hyperlipidemia.

따라서 최근 서구화된 식생활 및 내부요인에 의해 발생하는 고지혈증을 개선하기 위해서는 지질대사 이상을 조절할 필요가 있으며, 콜레스테롤 및 중성지방의 대사 이상을 모두 원활히 할 수 있는 기능성식품의 소재 개발이 요구되어 왔다.Therefore, in order to improve hyperlipidemia caused by westernized diet and internal factors, it is necessary to control lipid metabolism abnormalities, and it has been required to develop functional food materials capable of smoothing metabolic abnormalities of cholesterol and triglycerides.

대한민국 특허출원 제2005-32129호 및 대한민국 특허출원 제2005-32130호에 기재되어 있는 바에 따르면, 홍삼 산성다당체(RGAP)는 외인성 고지혈증에서는 콜레스테롤의 농도가 일정하게 유지되는 반면 중성지방의 함량에 대해서 특이적으로 그 농도가 감소되며 내인성 고지혈증에서는 콜레스테롤 및 중성지방의 농도가 함께 감소시키는 특성을 갖는다.As described in Korean Patent Application No. 2005-32129 and Korean Patent Application No. 2005-32130, red ginseng acid polysaccharide (RGAP) is specific for triglyceride content while maintaining a constant cholesterol level in exogenous hyperlipidemia. As a result, the concentration is decreased, and in endogenous hyperlipidemia, cholesterol and triglyceride levels are decreased together.

본 발명은 보다 증진된 고지혈증 개선 효과를 갖는 조성물에 관한 것으로서, 본 발명의 RGAP 및 구기자추출물을 함유한 생약조성물은 외인성 고지혈증이나 내인성 고지혈증 모두에서 중성지방 및 콜레스테롤의 농도를 동시에 감소시키므로 상기 조성물은 고지혈증 개선을 위해 효과적으로 이용될 수 있다.The present invention relates to a composition having an improved hyperlipidemic effect, wherein the herbal composition containing the RGAP and goji berry extract of the present invention simultaneously reduces the concentration of triglycerides and cholesterol in both exogenous hyperlipidemia and endogenous hyperlipidemia. It can be effectively used for improvement.

이하 본 발명을 상세히 설명한다.Hereinafter, the present invention will be described in detail.

본 발명의 RGAP는 홍삼으로부터 분리되고, 글루쿠론산(glucuronic acid) 41.6 내지 60.0몰%, 갈락투론산(galacturonic acid) 2.5 내지 7.5몰%, 글루코오스(glucose) 18.8 내지 33.4몰%, 아라비노오스(arabinose) 1.1 내지 2.1몰%를 포함하며, 분자량이 12,000 내지 450,000인 산성다당체이다. 상기 RGAP는 바람직하게는 대한민국 특허 제450061호의 방법에 의해 제조된다.RGAP of the present invention is isolated from red ginseng, glucuronic acid (glucuronic acid) 41.6 to 60.0 mol%, galacturonic acid (galacturonic acid) 2.5 to 7.5 mol%, glucose (glucose) 18.8 to 33.4 mol%, arabinose ( arabinose) is an acidic polysaccharide comprising 1.1 to 2.1 mol%, molecular weight of 12,000 to 450,000. The RGAP is preferably prepared by the method of Korean Patent No. 4,50061.

또한 본 발명의 구기자추출물은 통상적인 생약추출방법에 준하여 제조되며, 구기자 열매에 물 8배(v/w)를 가하고, 85℃에서 4 시간씩 3회 추출하여, 여과(whatman 41번) 및 농축한 후 동결건조하여 제조된다.In addition, the wolfberry extract of the present invention is prepared according to the conventional herbal medicine extraction method, 8 times water (v / w) is added to the wolfberry fruit, extracted three times at 85 ℃ 4 times, filtered (whatman 41 times) and concentrated After lyophilization.

본 발명은 식이요법에 의하여 외인성 고지혈증이나 내인성 고지혈증의 중성지방 및 콜레스테롤 농도를 동시에 감소시키기 위하여 RGAP 및 구기자추출물을 혼합 또는 병용하여 섭취할 수 있다. RGAP 및 구기자추출물의 생약추출물은 1:2 내지 1:3 중량비, 바람직하게는 1:2 중량 비율로 섭취할 수 있으나, 본 발명에 이에 국한되는 것은 아니다.The present invention can be ingested by mixing or in combination with RGAP and goji extract to simultaneously reduce the triglyceride and cholesterol concentrations of exogenous hyperlipidemia or endogenous hyperlipidemia by diet. The herbal extract of RGAP and goji berry extract may be ingested in a 1: 2 to 1: 3 weight ratio, preferably in a 1: 2 weight ratio, but is not limited thereto.

그리고 본 발명은 상기 생약조성물을 통상적인 기호성 식품에 첨가하여 통상적으로 알려진 방법에 의하여 각종 식품을 제조할 수 있고, 또한 일반적인 제형으로 제형화 될 수 있으며, 상기한 성분 이외에 다른 성분은 제형에 따라 당업자가 적의하게 선택하여 배합 할 수 있다.And the present invention can be prepared by a known method by adding the herbal composition to a conventional palatable food, can be prepared in a variety of foods, and also can be formulated in a general formulation, other ingredients other than the above components are those skilled in the art according to the formulation Can be selected and blended suitably.

이하, 본 발명을 실시예에 의하여 상세히 설명하고자 한다. 단 하기 실시예는 본 발명을 예시하기 위한 것일 뿐, 본 발명의 범위가 실시예에 의하여 한정되는 것은 아니다.Hereinafter, the present invention will be described in detail by examples. However, the following examples are only for illustrating the present invention, and the scope of the present invention is not limited by the examples.

<제조예 1> 홍삼 산성다당체(RGAP)의 제조Preparation Example 1 Preparation of Red Ginseng Acid Polysaccharide (RGAP)

RGAP는 대한민국 특허 제450061호에 기재된 방법에 따라 다음과 같이 제조되었다.RGAP was prepared as follows according to the method described in Korean Patent No. 4,50061.

홍삼 1kg에 85% 에탄올 10L를 첨가하여 70℃에서 3회 추출한 후 원심분리하여 잔사를 회수하고, 회수된 잔사를 통풍 건조시킨 후 80℃에서 10L의 물로 4회 추출하여 수용성 추출물을 얻었다. 상기 수용성 추출물을 분자량 컷오프(cut-off) 값이 12kD 이상인 투석막을 이용하여 냉장실에서 4일간 증류수로 투석하여 12kD 이상의 고분자 투석내액을 얻고 이를 8,000 rpm에서 20분 동안 원심분리하여 상등액을 얻었다. 상기 상등액에 상등액 5배 중량의 85% 에탄올을 첨가하여 침전시킨 후 이로부터 원심분리(8,000 rpm, 30분)하여 얻은 침전물을 냉동, 건조하여 RGAP를 제조하였다.10 g of red ginseng was added to 10 kg of 85% ethanol, and extracted three times at 70 ° C., followed by centrifugation to recover the residue. The aqueous extract was dialyzed with distilled water for 4 days in a refrigerating chamber using a dialysis membrane having a molecular weight cut-off value of 12 kD or more to obtain a polymer dialysis solution of 12 kD or more, which was centrifuged at 8,000 rpm for 20 minutes to obtain a supernatant. RGAP was prepared by freezing and drying the precipitate obtained by adding 85% ethanol 5 times the weight of the supernatant to the supernatant and centrifuging (8,000 rpm, 30 minutes) therefrom.

<제조예 2> 구기자 추출물의 제조Preparation Example 2 Preparation of Wolfberry Extract

구기자 1kg에 물 8 L를 넣고, 85℃에서 4시간씩 3회 추출하여 여과하고 농축한 후, 농축물을 동결건조하여 구기자 추출물을 제조하였다.8 L of water was added to 1 kg of goji berry, extracted three times at 85 ° C. for 4 hours, filtered and concentrated, and the concentrate was lyophilized to prepare a goji berry extract.

<제조예 3 내지 제조예 5> 홍삼 산성다당체 및 구기자 추출물의 조성물의 제조Preparation Examples 3 to 5 Preparation of Red Ginseng Acid Polysaccharide and Goji Extract

제조예 1의 RGAP 100 mg/kg과 제조예 2의 구기자(Lycium chinense; LC) 추출물 100, 200, 300 mg/kg을 각각 중량비 1:1, 1:2 및 1:3으로 혼합하여 각각 제조예 3 내지 제조예 5의 조성물을 제조하였다.RGAP 100 mg / kg of Preparation Example 1 and wolfberry of Preparation Example 2 ( Lycium chinense ; LC) 100, 200 and 300 mg / kg extracts were mixed in a weight ratio of 1: 1, 1: 2 and 1: 3, respectively, to prepare the compositions of Preparation Examples 3 to 5.

<실시예 1> 정제의 제조Example 1 Preparation of Tablet

상기 제조예 4에서 제조된 생약조성물 5.0 중량%에, 전분 65.0 중량%, 유당 17.5 중량%, 스테아린산마그네슘 5.0 중량%, 비타민 C 2.5 중량%, 만니톨 5.0 중량%를 배합하고 통상의 정제 제조방법으로 생약조성물을 함유하는 정제를 제조하였다.To 5.0% by weight of the herbal composition prepared in Preparation Example 4, 65.0% by weight of starch, 17.5% by weight of lactose, 5.0% by weight of magnesium stearate, 2.5% by weight of vitamin C, 5.0% by weight of mannitol, and the herbal medicine by a conventional tablet manufacturing method Tablets containing the composition were prepared.

<실시예 2> 캅셀제의 제조Example 2 Preparation of Capsule

상기 제조예 3에서 제조된 생약조성물 5.0 중량%에, 카복시메틸셀룰로스 90.0 중량%, 스테아린산마그네슘 5.0 중량%을 배합하고 통상의 캅셀제 제조방법으로 캅셀에 충전하여 생약조성물을 함유하는 캅셀제를 제조하였다.To 5.0% by weight of the herbal composition prepared in Preparation Example 3, 90.0% by weight of carboxymethyl cellulose and 5.0% by weight of magnesium stearate were blended and filled into capsules by a conventional method for preparing a capsule, thereby preparing a capsule containing the herbal composition.

<실시예 3> 국수의 제조Example 3 Preparation of Noodles

상기 제조예 5에서 제조된 생약조성물 분말 7 중량%에, 소맥분 48 중량%, 전분 37 중량%, 검정 콩가루 8 중량%을 배합하고 통상의 국수 제조방법으로 생약조성 물을 함유하는 국수를 제조 하였다.7% by weight of the herbal composition powder prepared in Preparation Example 5, 48% by weight of wheat flour, 37% by weight starch, 8% by weight of black soybean powder was prepared, and noodles containing the herbal composition was prepared by a conventional noodle manufacturing method.

<실시예 4> 음료의 제조Example 4 Preparation of Beverage

상기 제조예 4에서 제조한 생약조성물 7.0 중량%에, 농축사과과즙 13.0 중량%, 비타민 C 2.0 중량%, 구연산 15.0 중량%, 구연산삼나트륨 2.5 중량%, 드링크후레바, 안식향산나트륨 2.5 중량% 및 나머지는 정제수를 배합하여 90℃이상에서 20초간 살균하여 충전한 후 85℃에서 30분간 살균하여 생약조성물을 함유하는 음료를 제조하였다.To 7.0% by weight of the herbal composition prepared in Preparation Example 4, concentrated apple juice 13.0% by weight, vitamin C 2.0% by weight, citric acid 15.0% by weight, trisodium citrate 2.5% by weight, drink flavora, sodium benzoate 2.5% by weight and the rest Was prepared by mixing purified water with sterilization for 20 seconds at 90 ℃ or more and then sterilizing for 30 minutes at 85 ℃ to prepare a beverage containing a herbal composition.

<< 실험예Experimental Example 1> 항고지혈 효과 실험 1> Antihyperlipidemic Effect Experiment

가. 실험방법end. Experiment method

흰쥐(SP.D rat, 약 200g)에 제조예 1에서 제조된 RGAP의 100㎎/㎏ 및 300㎎/㎏, 제조예 2의 구기자 추출물 200㎎/㎏ 및 300㎎/㎏, 제조예 4에서 제조된 생약조성물(1: 2 중량비) 300 ㎎/㎏의 시료 각각을 1회/일, 3일동안 경구투여한 후 12 시간 동안 절식시켰다. 각 시료를 다시 1회 경구투여한 후 1 시간 후 트리톤(Triton WR-1339)을 흰쥐의 꼬리정맥에 투여(200 ㎎/㎏)하여 고지혈증을 유발하였다. 2 시간 후에 혈액을 채취하여 생화학분석기(Automatic Analyzer, Hitachi 7020, Tokyo, Japan)로 고지혈 관련 지수를 측정하고 그 결과를 표 1 에 나타내었다. 정상군은 고지혈증을 유발하지 않은 군이고, 대조군은 상기 시료군과 동일하게 트리톤을 투여하고 아무런 처치도 하지 않은 군이다.100 mg / kg and 300 mg / kg of RGAP prepared in Preparation Example 1, 200mg / kg and 300mg / kg of Gojija extract of Preparation Example 2, prepared in Preparation Example 4 in rats (SP.D rat, about 200g) Each of the prepared herbal compositions (1: 2 weight ratio) 300 mg / kg was orally administered once / day for 3 days and then fasted for 12 hours. One hour after oral administration of each sample, Triton WR-1339 was administered to the tail vein of the rat (200 mg / kg) to induce hyperlipidemia. After 2 hours, blood was collected, and the index of hyperlipidemia was measured by a biochemical analyzer (Automatic Analyzer, Hitachi 7020, Tokyo, Japan), and the results are shown in Table 1. The normal group was a group that did not cause hyperlipidemia, and the control group was a group treated with Triton and not treated in the same manner as the sample group.

시료투여군에서 대조군 대비 저해율은 「(대조군의 혈중농도 - 시료투여군의 혈중농도)/ (대조군의 혈중농도-정상군의 혈중농도) x 100」의 계산법으로 나타내었다.Inhibition rate compared to the control group in the sample administration group was expressed by the calculation method of ((blood concentration of the control group-blood concentration of the sample administration group) / (blood concentration of the control group-blood concentration of the normal group) x 100.

나. 실험결과I. Experiment result

시험군Test group 투여용량(㎎/㎏)Dose (mg / kg) 총콜레스테롤 (total chlolesterol) (mg/dl)Total Cholesterol (total chlolesterol) (mg / dl) 중성지방 (triglyceride) (mg/dl)Triglyceride (mg / dl) 트리톤Triton 시료sample 정상군  Normal -- -- 63.9± 10.9  63.9 ± 10.9 70.3± 20.0  70.3 ± 20.0 대조군   Control 200200 -- 127.4± 18.2** 127.4 ± 18.2 ** 474.3± 52.7** 474.3 ± 52.7 ** RGAP 100RGAP 100 200200 100100 125.0± 25.7 (3.8%) 125.0 ± 25.7 (3.8%) 437.3± 90.9 (9.2%) 437.3 ± 90.9 (9.2%) LC 200LC 200 200200 200200 121.5± 17.9 (9.3%) 121.5 ± 17.9 (9.3%) 463.9± 80.9 (2.6%) 463.9 ± 80.9 (2.6%) RGAP 300RGAP 300 200200 300300 124.9± 19.8 (3.9%) 124.9 ± 19.8 (3.9%) 412.6± 87.6 (15.3%) 412.6 ± 87.6 (15.3%) LC 300LC 300 200200 300300 120.1± 16.5 (11.5%) 120.1 ± 16.5 (11.5%) 421.2± 95.4 (13.1%) 421.2 ± 95.4 (13.1%) 생약조성물 (1:2) (RGAP100mg/kg + LC 200mg/kg)Herbal Composition (1: 2) (RGAP100mg / kg + LC 200mg / kg) 200200 300300 94.8± 9.0**,## (51.3%)94.8 ± 9.0 **, ## (51.3%) 341.4± 98.8**,# (32.9%)341.4 ± 98.8 **, # (32.9%) RGAP: 홍삼산성다당체, LC: 구기자 추출물 *, ** p<0.05, p < 0.01 정상대조군 vs 대조군 #,## p<0.05, p<0.01 대조군 vs 투여군 ( ): 대조군 대비 저해율 % RGAP: red ginseng acid polysaccharide, LC: goji berry extract *, ** p <0.05, p <0.01 normal control vs control #, ## p <0.05, p <0.01 control vs administration ():% inhibition compared to control

상기 표 1에서 알 수 있는 바와 같이, 트리톤을 투여하여 고지혈증이 유발된 흰쥐에서 총콜레스테롤 함량이 정상군의 63.9㎎/㎗에서 대조군은 127.4㎎/㎗로 약 2배의 농도증가가 유도되었으며, 중성지방 함량도 정상군의 70.3㎎/㎗에서 대조군은 474.3㎎/㎗로 약 7배의 농도증가가 유도된 것으로서, 각 시료에 의하여 각 농도가 저해된 것을 나타낸 것이다.As can be seen in Table 1, in the hyperlipidemia-induced triglyceride-induced rats, the total cholesterol content was 63.9 mg / dL in the normal group and 127.4 mg / dL in the control group, causing about two-fold increase in concentration. The fat content of 70.3 mg / dl of the normal group was 474.3 mg / dl of the control group, which was induced by an increase of about 7 times, indicating that each concentration was inhibited by each sample.

RGAP 단독으로 100 및 300㎎/㎏ 투여의 경우 혈중 총콜레스테롤 함량은 3.8% 및 3.9% 저해하였고, 구기자추출물 단독 200 및 300㎎/㎏ 투여는 9.3% 및 11.5% 저해에 불과 하였으나, 본 발명의 생약 조성물(RGAP 100㎎/㎏ + LC 200㎎/㎏)의 경우에는 혈중 총콜레스테롤 함량을 51.3% 저해함으로서, 본 발명의 생약조성물이 단독투여군보다 혈중 총콜레스테롤 저해율이 현저하게 증가하였음을 알 수 있다. 상기 결과로부터 본 발명의 혈중 총콜레스테롤 감소 효과는 시너지효과를 나타내어 매우 우수한 것임을 알 수 있다.In the case of 100 and 300 mg / kg administration alone, the total cholesterol content in blood was inhibited by 3.8% and 3.9%, and the administration of goji berry extract 200 and 300 mg / kg alone was only 9.3% and 11.5% inhibition. In the case of the composition (RGAP 100 mg / kg + LC 200 mg / kg) by inhibiting the blood total cholesterol content by 51.3%, it can be seen that the herbal composition of the present invention significantly increased the blood total cholesterol inhibition rate than the single administration group. From the above results, it can be seen that the total cholesterol reduction effect of the present invention is very excellent due to the synergistic effect.

또한 RGAP 단독 100 및 300㎎/㎏ 투여의 경우 혈중 중성지방 함량을 9.2% 및 15.3% 저해하였고, 구기자추출물 단독 200 및 300㎎/㎏ 투여는 2.6% 및 13.1% 저해에 불과 하였으나, 본 발명의 생약 조성물(RGAP 100㎎/㎏ + LC 200㎎/㎏)의 경우에는 혈중 중성지방 함량을 32.9% 저해함으로서, 본 발명의 생약조성물이 단독투여군보다 혈중 중성지방 저해율이 현저하게 증가하였음을 알 수 있다. 상기 실험 결과는 본 발명의 혈중 중성지방 감소 효과는 시너지 효과를 나타내어 매우 우수한 것임을 알 수 있다.In addition, RGAP alone inhibited 9.2% and 15.3% in the content of triglyceride in the blood by 100 and 300 mg / kg, whereas 200 and 300 mg / kg administration of Goji extract alone inhibited only 2.6% and 13.1%. In the case of the composition (RGAP 100mg / kg + LC 200mg / kg) by inhibiting the blood triglyceride content by 32.9%, it can be seen that the herbal composition of the present invention significantly increased the blood triglyceride inhibition rate than the single administration group. The experimental results indicate that the effect of reducing triglycerides in the blood of the present invention shows a synergistic effect and is very excellent.

그러므로 본 발명은 콜레스테롤 및 중성지방 모두에 대하여 고지혈증 개선 기능을 나타내었을 뿐만 아니라, RGAP 및 구기자 추출물 단독 투여에 비하여 콜레스테롤 및 중성지방 감소 효과는 매우 우수한 시너지 효과를 나타내었다.Therefore, the present invention not only showed an improvement in hyperlipidemia for both cholesterol and triglycerides, but also showed a very synergistic effect of reducing cholesterol and triglycerides compared to RGAP and goji extract.

<< 실험예Experimental Example 2> 본 발명의 조성비 변화에 따른 항고지혈 효과 비교 2> Comparison of antihyperlipidemic effect according to the change of composition ratio of the present invention

가. 실험방법end. Experiment method

제조예 1의 RGAP 100 mg/kg과 제조예 2의 구기자(Lycium chinense; LC) 추출물 100, 200, 300 mg/kg을 1:1, 1:2, 1:3의 비율로 조합한 각 제조예 3 내지 5를 실험예 1의 방법에 따라 각각의 조성물을 1회/일, 3일동안 경구투여한 후 12 시간 동안 절식시켰다. 생약조성물을 다시 1회 경구투여한 후 1 시간 후 트리톤(Triton WR-1339)을 흰쥐의 꼬리정맥에 투여 (200 mg/kg)하여 고지혈증을 유발하였다. 2 시간후 혈액을 채취하여 생화학분석기(Automatic Analyzer, Hitachi 7020, Tokyo, Japan)로 고지혈 관련 지수를 측정하고 그 결과를 표 2에 나타내었다. 정상군은 고지혈증을 유발하지 않은 군이고, 대조군은 상기 시료군과 동일하게 트리톤을 투여하고 아무런 처치도 하지 않은 군이다.RGAP 100 mg / kg of Preparation Example 1 and wolfberry of Preparation Example 2 ( Lycium chinense ; LC) Extract 100, 200, 300 mg / kg of each of the preparations 3 to 5 in a ratio of 1: 1, 1: 2, 1: 3 each composition according to the method of Experimental Example 1 once / day After 3 days of oral administration and fasting for 12 hours. After oral administration of the herbal composition once again, Triton (WR-1339) was administered to the tail vein of rats (200 mg / kg) to induce hyperlipidemia. After 2 hours, blood was collected, and the index of hyperlipidemia was measured by a biochemical analyzer (Automatic Analyzer, Hitachi 7020, Tokyo, Japan), and the results are shown in Table 2. The normal group was a group that did not cause hyperlipidemia, and the control group was a group treated with Triton and not treated in the same manner as the sample group.

저해율은 「(대조군의 혈중농도 - 시료투여군의 혈중농도)/ (대조군의 혈중농도-정상군의 혈중농도) x 100」의 계산법으로 나타내었다.The inhibition rate was expressed by the calculation method of "(blood concentration of control group-blood concentration of sample administration group) / (blood concentration of control group-blood concentration of normal group) x 100".

나. 실험결과I. Experiment result

시험군 (n=10)Test group (n = 10) 1회 투여용량(mg/kg)Single dose (mg / kg) 총 콜레스테롤 (mg/dl)  Total cholesterol (mg / dl) 중성지방 (mg/dl)Triglycerides (mg / dl) 트리톤Triton 시료sample 정상군 Normal -- -- 63.9± 11.063.9 ± 11.0 70.3± 20.070.3 ± 20.0 대조군 Control 200200 -- 127.4± 18.2** 127.4 ± 18.2 ** 474.3± 52.7** 474.3 ± 52.7 ** 제조예 3Preparation Example 3 200200 200200 119.5± 30.6** (12.4%)119.5 ± 30.6 ** (12.4%) 425.0± 118.3** (12.2%)425.0 ± 118.3 ** (12.2%) 제조예 4Preparation Example 4 200200 300300 94.8± 9.0**,## (51.3%)94.8 ± 9.0 **, ## (51.3%) 341.4± 98.8**,## (32.9%)341.4 ± 98.8 **, ## (32.9%) 제조예 5Preparation Example 5 200200 400400 110.1± 18.3** (27.2%)110.1 ± 18.3 ** (27.2%) 342.8± 48.5**,## (32.5%)342.8 ± 48.5 **, ## (32.5%) *, **: p<0.05, p<0.01 정상군 vs 대조군 #, ##: p<0.05, p<0.01 대조군 vs 시료투여군 RGAP: 홍삼산성다당체, LC: 구기자추출물 ( ): 혈중농도 저해율 % *, **: p <0.05, p <0.01 normal vs control #, ##: p <0.05, p <0.01 control vs sample administration RGAP: red ginseng polysaccharide, LC: goji berry extract (): blood concentration inhibition%

상기 표 2에서 나타낸 바와 같이, 제조예 3의 생약조성물(1: 1 중량비) 투여군은 총콜레스테롤 함량이 119.5 ㎎/㎗이고 중성지방 함량이 425.0㎎/㎗으로서 각각 12.4% 및 12.2%의 저해를 하였으며, 제조예 4의 생약조성물(1: 2 중량비) 투여군은 총콜레스테롤 함량이 94.8㎎/㎗이고 중성지방 함량이 341.4㎎/㎗로서 각각 51.3% 및 32.9%의 저해를 하였고, 제조예 5의 생약조성물(1: 3 중량비) 투여군은 총콜레스테롤 함량이 110.1㎎/㎗이고 중성지방 함량이 342.80㎎/㎗로서 각각 27.2% 및 32.5%의 저해를 하였음을 알 수 있다.As shown in Table 2, the herbal composition (1: 1 weight ratio) administration group of Preparation Example 3 had a total cholesterol content of 119.5 mg / dl and a triglyceride content of 425.0 mg / dl, inhibiting 12.4% and 12.2%, respectively. The herbal composition (1: 2 weight ratio) administration group of Preparation Example 4 had a total cholesterol content of 94.8 mg / dl and a triglyceride content of 341.4 mg / dl, inhibiting 51.3% and 32.9%, respectively. (1: 3 weight ratio) The administration group showed a total cholesterol content of 110.1 mg / dl and a triglyceride content of 342.80 mg / dl, inhibiting 27.2% and 32.5%, respectively.

그러므로 제조예 3 내지 5의 생약조성물은 실험예 1의 표 1에 의한 단독투여군보다는 콜레스테롤 및 중성지방의 저해 효과가 높거나 동등 이상으로서 RGAP 및 구기자추출물의 생약추출물은 특정 비율이 아니더라도 시너지효과를 나타냄을 알 수 있다.Therefore, the herbal compositions of Preparation Examples 3 to 5 had higher or equivalent inhibitory effect of cholesterol and triglyceride than the alone administration group according to Table 1 of Experimental Example 1, and the herbal extracts of RGAP and goji berry extract showed synergistic effect even if not in a specific ratio. It can be seen.

본 발명은 홍삼 산성다당체(RGAP) 및 구기자(Lycium chinense)추출물을 함유하며, 보다 강화된 고지혈증 개선 기능을 갖는 건강기능식품 조성물을 제공한다.The present invention red ginseng acid polysaccharide (RGAP) and gojija ( Lycium chinense ) extract, and provides a nutraceutical composition with enhanced hyperlipidemia improving function.

특히, 본 발명은 콜레스테롤 및 중성지방 모두에 대하여 고지혈증 개선 기능을 나타낼 뿐만 아니라 단독의 RGAP 및 구기자추출물이 갖는 고지혈증 개선 기능 이상의 시너지효과에 의해 고지혈증 개선 기능을 갖는다.In particular, the present invention not only exhibits hyperlipidemia improving function for both cholesterol and triglyceride, but also has hyperlipidemia improving function due to synergistic effects of hyperlipidemia improving function of RGAP and goji berry extract alone.

따라서 본 발명은 중성지방뿐만 아니라 콜레스테롤의 농도를 모두 감소시킴 으로써 지방 섭취량이 많은 현대인의 식생활 및 유전적 요인 등에 의해 발생하는 고지혈증의 개선을 위해 식이요법으로 유용하게 사용될 수 있다.Therefore, the present invention can be usefully used as a diet for the improvement of hyperlipidemia caused by the dietary and genetic factors of modern people with high fat intake by reducing both the concentration of cholesterol as well as triglycerides.

Claims (2)

글루쿠론산(glucuronic acid) 41.6 내지 60.0몰%, 갈락투론산(galacturonic acid) 2.5 내지 7.5몰%, 글루코오스(glucose) 18.8 내지 33.4몰%, 아라비노오스(arabinose) 1.1 내지 2.1몰%을 포함하며 분자량이 12,000 내지 450,000인 홍삼산성다당체(Red ginseng acid polysaccharide: RGAP) 및 구기자(Lycium chinense) 추출물을 유효성분으로 함유하는 항고지혈증제.41.6 to 60.0 mol% of glucuronic acid, 2.5 to 7.5 mol% of galacturonic acid, 18.8 to 33.4 mol% of glucose, and 1.1 to 2.1 mol% of arabinose. Red ginseng acid polysaccharide (RGAP) and gojija ( Lycium ) having a molecular weight of 12,000 to 450,000 chinense ) Antihyperlipidemic agent containing extract as an active ingredient. 제 1 항에 있어서, 항고지혈증은 콜레스테롤 및 중성지방 저해 효과를 나타냄을 특징으로 하는 항고지혈증제. The antihyperlipidemic agent according to claim 1, wherein the antihyperlipidemia shows cholesterol and triglyceride inhibitory effects.
KR1020070041348A 2007-04-27 2007-04-27 Antihyperlipidemia Agent Comprising Red Ginseng Acid Polysaccharide and Lycium Chinense Extract KR100815277B1 (en)

Priority Applications (1)

Application Number Priority Date Filing Date Title
KR1020070041348A KR100815277B1 (en) 2007-04-27 2007-04-27 Antihyperlipidemia Agent Comprising Red Ginseng Acid Polysaccharide and Lycium Chinense Extract

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
KR1020070041348A KR100815277B1 (en) 2007-04-27 2007-04-27 Antihyperlipidemia Agent Comprising Red Ginseng Acid Polysaccharide and Lycium Chinense Extract

Related Parent Applications (1)

Application Number Title Priority Date Filing Date
KR1020050115976 Division 2005-11-30

Publications (2)

Publication Number Publication Date
KR20070061493A true KR20070061493A (en) 2007-06-13
KR100815277B1 KR100815277B1 (en) 2008-03-19

Family

ID=38357313

Family Applications (1)

Application Number Title Priority Date Filing Date
KR1020070041348A KR100815277B1 (en) 2007-04-27 2007-04-27 Antihyperlipidemia Agent Comprising Red Ginseng Acid Polysaccharide and Lycium Chinense Extract

Country Status (1)

Country Link
KR (1) KR100815277B1 (en)

Cited By (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
KR100880804B1 (en) * 2007-06-12 2009-01-30 주식회사 케이티앤지 Health Functional Food Compositions Comprising Red Ginseng Acid Polysaccharide and Lycium Chinense Extract for Improving Hyperlipidemia
US20120164245A1 (en) * 2009-09-04 2012-06-28 Munisekhar Medasani Method of treatment of neurodegenerative or neuro-muscular degenerative diseases and therapeutic agent to treat the same

Families Citing this family (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
KR101064084B1 (en) 2010-03-25 2011-09-08 엘지이노텍 주식회사 Light emitting device package and fabrication method thereof

Family Cites Families (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
KR100450061B1 (en) * 2001-06-13 2004-09-24 주식회사 한국인삼공사 Novel acid polysaccharide having anti-cancer immunoregulatory effect which is purified from red ginseng and composition for anti-cancer immunoreguation comprising same

Cited By (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
KR100880804B1 (en) * 2007-06-12 2009-01-30 주식회사 케이티앤지 Health Functional Food Compositions Comprising Red Ginseng Acid Polysaccharide and Lycium Chinense Extract for Improving Hyperlipidemia
US20120164245A1 (en) * 2009-09-04 2012-06-28 Munisekhar Medasani Method of treatment of neurodegenerative or neuro-muscular degenerative diseases and therapeutic agent to treat the same
US8962039B2 (en) * 2009-09-04 2015-02-24 Munisekhar Medasani Method of treatment of neurodegenerative or neuro-muscular degenerative diseases and therapeutic agent to treat the same

Also Published As

Publication number Publication date
KR100815277B1 (en) 2008-03-19

Similar Documents

Publication Publication Date Title
KR101346244B1 (en) Composition for preventing or relieving alcohol-induced hangover comprising medicinal herbs
KR101281988B1 (en) Composition having eleutherococcus senticosus for treating hangover and improving liver function, and the preparation method thereof
JP5275251B2 (en) Composition comprising an extract of a combined herb for preventing and treating liver disease
KR100815277B1 (en) Antihyperlipidemia Agent Comprising Red Ginseng Acid Polysaccharide and Lycium Chinense Extract
KR100953813B1 (en) Composition comprising the extract of mixed herb suppressing lipid generation for preventing and treating fatty liver disease
CN110604773B (en) Composition for regulating lipid metabolism disorder and preparation method and application thereof
CN106581166A (en) Anti-fatigue food, health product or pharmaceutical composition
KR100832321B1 (en) Healthy food comprising Red ginseng acid polysaccharide for hyperlipidemia improvement
KR20140108104A (en) Compositions comprising the combined extract of Artemisia iwayomogi and Curcuma longa for treating, inhibiting or preventing obesity-related disease
KR100784169B1 (en) healthy and functional food for constipation improvement
KR20220067467A (en) A composition comprising the ethanol extract of Corchorus olitorius for the prevention or treatment of alcoholic liver damage
KR20150046916A (en) Compositions for treating or preventing liver fibrosis or cirrhosis
KR100315001B1 (en) Herbal Medicine for the Treatment of Diabetes Mellitus Containing Enteric Bellflower Extract
CN109316565B (en) Blood fat reducing composition and preparation method and application thereof
KR100880804B1 (en) Health Functional Food Compositions Comprising Red Ginseng Acid Polysaccharide and Lycium Chinense Extract for Improving Hyperlipidemia
KR101420270B1 (en) Composition comprising reacted mixture of red ginseng extract and persimmon vinegar for preventing or treating benign prostatic hyperplasia
KR101181347B1 (en) Composition for the prevention and treatment of lipid-related cardiovascular disease or obesity containing the extracts of Dictamnus dasycarpus as active ingredient
JP4323128B2 (en) Bioactive composition
JP2009024027A (en) Physiologically active composition
KR100888068B1 (en) Compositions for suppressing obesity
JPS59106276A (en) Health food
KR100504124B1 (en) Mixture for prevention of obesity
KR100733333B1 (en) Pharmaceutical composition comprising red ginseng acid polysaccharide for treating hyperlipidemia
CN103110675A (en) Soft capsule for improving alimentary anemia and preparation method thereof
US20240123019A1 (en) Composition for treating or ameliorating liver disease and liver dysfunction comprising zizania latifolia extract

Legal Events

Date Code Title Description
A107 Divisional application of patent
A201 Request for examination
E902 Notification of reason for refusal
E701 Decision to grant or registration of patent right
GRNT Written decision to grant
FPAY Annual fee payment

Payment date: 20130218

Year of fee payment: 6

FPAY Annual fee payment

Payment date: 20140227

Year of fee payment: 7

FPAY Annual fee payment

Payment date: 20150223

Year of fee payment: 8

FPAY Annual fee payment

Payment date: 20170303

Year of fee payment: 10

FPAY Annual fee payment

Payment date: 20180227

Year of fee payment: 11

FPAY Annual fee payment

Payment date: 20190305

Year of fee payment: 12

FPAY Annual fee payment

Payment date: 20200204

Year of fee payment: 13